Jose Drabwell Research Grant Programme Winners

,

The IPOPI Jose Drabwell Research Grant Programme is an initiative aimed at promoting scientific and clinical research in the field of primary immunodeficiencies.

The third grant call in 2026, supported by Grifols and Kedrion, ran from June to August, inviting applicants from around the world to seize the opportunity to fuel innovation in the field with patient-centred and knowledge-generating projects.

IPOPI is pleased to announce the winners of the IPOPI Jose Drabwell Research Grant Programme 2026. The winners will receive funding for 2 years to carry out the following:

 

  • Dr Narissara Suratannon

Affiliation: Center of Excellence for Allergy and Clinical Immunology, Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, and the King Chulalongkorn Memorial Hospital, the Thai Red Cross Society, Bangkok, Thailand

Project Title: Establishing a Southeast Asian Gene Therapy Hub for Inborn Errors of Immunity Using RAG1-SCID as a Pioneering Program

📌 This project evaluates whether measuring TREC and KREC levels can serve as cost-effective tools to support early screening and diagnosis of inborn errors of immunity in Vietnamese pediatric patients.

 

  • Dr Jolan Walter

Affiliation: University of South Florida, United States of America

Project Title: Serum biomarkers of immune dysregulation to assess disease state in monogenic combined immunodeficiencies: from research to patient education

🔬 This project will develop and validate blood-based immune biomarkers and a patient-centred risk score to predict disease deterioration in people with G-CIDs, while improving patient understanding of biomarker monitoring and multiomics research.

 

  • Dr Katie Townsend

Affiliation: University College London, United Kingdom

Project Title: Integrating B-cell functional assays to improve the diagnosis of primary Predominantly Antibody Deficiencies

🌍 This project will develop a standardised B-cell functional testing platform to improve diagnosis and interpretation of genetic variants in patients with predominantly antibody deficiencies, including those without a confirmed genetic diagnosis.

 

We wish the winners the best of luck and success on these projects and would like to thank everyone who applied.

/by